focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 23.00
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 3.00 (13.043%)
Open: 24.50
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Elixirr meets guidance, in strong start to 2023

Mon, 27th Feb 2023 10:37

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Elixirr International PLC, up 20% at 503.0 pence, 12-month range 412p-780p. The consultancy firm says 2022 was a strong year, with all metrics to be "in line or above" market expectations. Revenue is expected to rise 40% to GBP70.7 million, within previous guidance, and adjusted earnings before interest, tax, depreciation and amortisation is expected at GBP20.4 million - which is in line with Elixirr's guidance of exceeding GBP20 million. Says 2023 has started "strongly" with an acceleration of organic growth in the first quarter, and January seeing record monthly revenue.

----------

Directa Plus PLC, up 10% at 87p, 12-month range 76p-87p. The graphene nanoplatelet products producer and supplier says revenue in 2022 is now expected at not less than EUR10.8 million, which is up from EUR10.0 million communicated back in December's trading update. This represents a 25% increase year-on-year. Says momentum has continued into 2023, with trading meeting market expectations, which Directa cites as revenue of EUR13.5 million for the year.

----------

AIM - LOSERS

----------

Hercules Site Services PLC, down 38% at 44.99p, 12-month range 40p-73p. The labour supply company for the UK infrastructure sector raises GBP1.7 million in a placing of 3.8 million shares at issue price of 45p - which represents a 24% discount to Friday's closing price of 59p. "With a strong 2023 pipeline in place, these funds will support further organic growth in our Labour Supply division, which represented over 67% of our revenue in 2022," says Chief Executive Brusk Korkmaz.

----------

Oncimmune Holdings PLC, down 23% at 42p, 12-month range 36.69p-146.0p. The immuno-diagnostics developer says, in the 15 months to August 31, revenue was GBP3.8 million, little changed from GBP3.7 million in the year to May 31. Pretax loss widens to GBP11.6 million from GBP6.1 million across the same time frame. However, says revenue in the first six months of financial 2023 are expected to exceed GBP3.8 million, and it expects to be operating cashflow positive during the year.

----------

Forward Partners Group PLC, down 6.5% at 36p, 12-month range 35p-98.4p. The early-stage technology-focused investor says the fair value of its portfolio fell 40% to no less than GBP79.0 million at December 31, from GBP117.1 million a year before. Net asset value per share is expected to plunge to 71.0p from 104p a year before. The investment firm blamed valuation headwinds, "due to public market and macroeconomic pressures". "Despite the pressure on valuations many of them still grew rapidly," says Chief Executive Nic Brisbourne.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 May 2019 12:59

Oncimmune begins study to bring 'EarlyCDT-Lung' to China

(Sharecast News) - Oncimmune Holdings, alongside its partner Genostics Company, announced the start of a multi-centre case control study on early lung cancer detection for screening and nodules in the People's Republic of China on Friday, using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.

Read more
10 May 2019 11:36

Oncimmune And Genostics Initiate Trial Of EarlyCDT-Lung In China

LONDON (Alliance News) - Oncimmune Holdings PLC and Genostics Co Ltd on Friday said a multi-centre case control study on early lung cancer detection in China has started.The company said is

Read more
5 Apr 2019 15:10

Oncimmune inks distribution deal for lung cancer test in Portugal

(Sharecast News) - Personalised immunodiagnostics developer Oncimmune Holdings has signed an exclusive agreement for the distribution of its 'EarlyCDT-Lung' test kit in Portugal with Sabartech, its existing distributor in Spain, it announced on Friday.

Read more
5 Apr 2019 10:04

Oncimmune Signs Lung Cancer Test Kit Distribution Deal With Sabartech

LONDON (Alliance News) - Cancer diagnostics company Oncimmune Holdings PLC on Friday said it has signed an exclusive agreement for the distribution of its lung cancer test kit in Portgual with can

Read more
2 Apr 2019 10:50

Oncimmune strengthens scientific board with addition of Parag Mallick

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the appointment of Dr Parag Mallick - an associate professor of radiology at Stanford University - to its scientific board on Tuesday.

Read more
19 Mar 2019 12:19

Oncimmune Buys Protagen Diagnostics In EUR4 Million All-Share Deal (ALLISS)

LONDON (Alliance News) - Cancer testing firm Oncimmune Holdings PLC said Tuesday it acquired protein biomarker laboratory Protagen Diagnostics AG for EUR4.1 million in an all-share will buy the of

Read more
19 Mar 2019 09:10

Oncimmune acquires Protagen Diagnostics in £4.11m deal

(Sharecast News) - Oncimmune Holdings has acquired Protagen Diagnostics for a total consideration of up to £4.11m, it announced on Tuesday, to be paid by the allotment of up to 2,635,910 Oncimmune ordinary shares at 156p each 0 a premium of 71% to the closing mid-market price on 18 March.

Read more
13 Feb 2019 10:45

Oncimmune Loss Widens In First Half On Administrative Costs

LONDON (Alliance News) - Cancer diagnostics business Oncimmune Holdings PLC on Wednesday said its loss widened in the first half its year on higher administrative expenses.In the six months

Read more
13 Feb 2019 09:20

Oncimmune Holdings' loss deepens on spiralling costs

(Sharecast News) - Oncimmune Holdings reported a widened interim loss on Wednesday as increases to research & development costs and administrative costs outweighed a rise in revenue.

Read more
20 Dec 2018 16:27

Oncimmune buoyed by US distribution deal for blood tests

(Sharecast News) - Oncimmune Holdings made gains on Thursday after it entered an agreement with America's Choice Provider Network to expand access to its EarlyCDT-Lung and EarlyCDT-Liver blood tests.

Read more
6 Dec 2018 17:39

Oncimmune Appoints Former Tusk Therapeutics CFO Matthew Hall To Board

LONDON (Alliance News) - Cancer diagnostics firm Oncimmune Holdings PLC on Thursday said its has appointed former Tusk Therapeutics Ltd Chief Financial Officer Matthew Hall as finance will replace

Read more
28 Nov 2018 11:57

Oncimmune signs sales deals in multiple countries for 'EarlyCDT-Lung' test

(Sharecast News) - Immunodiagnostics developer Oncimmune Holdings has signed exclusive agreements for the distribution of its 'EarlyCDT-Lung' test in Germany with hrmed.tech, in France with Eurobio Scientific, and in Italy with BSN, it announced on Wednesday.

Read more
31 Oct 2018 09:19

Oncimmune Annual Loss Deepens As Costs Hurt, Chases Cancer Test Deals

LONDON (Alliance News) - Oncimmune Holdings PLC said Wednesday its full year loss deepened on higher costs as it continues to chase new distribution deals for its cancer detection blood test the a

Read more
1 Oct 2018 12:47

Oncimmune inks multiple new distribution agreements

(Sharecast News) - Oncimmune revealed on Monday that it had signed multiple new distribution agreements for its EarlyCDT-Lung test as part of an early morning trading update.

Read more
25 Sep 2018 17:21

Oncimmune Says Lung Cancer Blood Test Outperforms Risk Calculator

LONDON (Alliance News) - Pharma company Oncimmune Holdings PLC on Tuesday said its lung cancer blood test, EarlyCDT-Lung, has proven to be more effective than a standard risk produced a positive a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.